- Home
- PSTL vs ALDX Comparison
PSTL vs ALDX Comparison
Compare PSTL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSTL | ALDX |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.8M | 293.0M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PSTL | ALDX |
|---|---|---|
| Price | $17.55 | $4.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.58 | $9.50 |
| AVG Volume (30 Days) | 249.6K | ★ 890.1K |
| Earning Date | 02-25-2026 | 02-27-2026 |
| Dividend Yield | ★ 5.59% | N/A |
| EPS Growth | ★ 508.95 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $91,195,000.00 | N/A |
| Revenue This Year | $25.74 | N/A |
| Revenue Next Year | $14.38 | $36.25 |
| P/E Ratio | $35.89 | ★ N/A |
| Revenue Growth | ★ 26.65 | N/A |
| 52 Week Low | $12.26 | $1.14 |
| 52 Week High | $17.44 | $7.20 |
Technical Indicators
Market Signals| Indicator | PSTL | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 81.72 | 51.82 |
| Support Level | $15.86 | $3.95 |
| Resistance Level | $16.14 | $4.33 |
| Average True Range (ATR) | 0.30 | 0.29 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 97.25 | 57.14 |
Price Performance
Historical ComparisonAbout PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.